Latest Articles
SMARCA4-deficient Undifferentiated Carcinoma Co-existing with Primary Endometrial Gastric (or Gastrointestinal) -Type Carcinoma：A Case Report - Frontiers
SMARCA4-deficient Undifferentiated Carcinoma Co-existing with Primary Endometrial Gastric (or Gastrointestinal) -Type Carcinoma：A Case Report Frontiers
Published: Feb. 10, 2025, 2:08 p.m.
Concurrent Inguinal Endometriosis and Catamenial Pneumothorax: A Case Report - Cureus
Concurrent Inguinal Endometriosis and Catamenial Pneumothorax: A Case Report Cureus
Published: Feb. 9, 2025, 12:56 a.m.
Inhibition of lanosterol synthase linking with MAPK/JNK signaling pathway suppresses endometrial cancer - Nature.com
Inhibition of lanosterol synthase linking with MAPK/JNK signaling pathway suppresses endometrial cancer Nature.com
Published: Feb. 8, 2025, 1:17 p.m.
Trauma Linked to Increased Risk of Endometriosis - Technology Networks
Trauma Linked to Increased Risk of Endometriosis Technology Networks
Published: Feb. 6, 2025, 4:10 p.m.
Childhood trauma may increase the risk of endometriosis | Faculty of Medicine | UiB - uib.no
Childhood trauma may increase the risk of endometriosis | Faculty of Medicine | UiB uib.no
Published: Feb. 6, 2025, 9:58 a.m.
Childhood trauma may increase the risk of endometriosis | Faculty of Medicine | UiB - Universitetet i Bergen
Childhood trauma may increase the risk of endometriosis | Faculty of Medicine | UiB Universitetet i Bergen
Published: Feb. 6, 2025, 9:58 a.m.
Real world perspectives on endometriosis disease phenotyping through surgery, omics, health data, and artificial intelligence - Nature.com
Real world perspectives on endometriosis disease phenotyping through surgery, omics, health data, and artificial intelligence Nature.com
Published: Feb. 6, 2025, 5 a.m.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Medpage Today
Published: Feb. 5, 2025, 5:54 p.m.
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent - Imaging Technology News
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent Imaging Technology News
Published: Feb. 5, 2025, 3:56 p.m.
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent - StreetInsider.com
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent StreetInsider.com
Published: Feb. 5, 2025, 1:51 p.m.
Link copied to clipboard!